Phytochem Remedies IPO GMP

December 19, 2025 Written By Mihir Gohel, Reviewed and Fact Checked by Harpal Parmar

Phytochem Remedies IPO opens for subscription from December 18 to 22, 2025, with shares listing on BSE SME on December 26, 2025. The fixed price issue raises ₹38.22 crore through 39 lakh fresh shares at ₹98 per share. Phytochem Remedies (India) Limited, based in Jammu, specializes in pharmaceutical and FMCG packaging solutions, reporting revenue growth from ₹20.83 crore in FY23 to ₹36.81 crore in FY25 and PAT of ₹4.48 crore in FY25. The Phytochem Remedies IPO offers exposure to India’s packaging sector growth driven by pharma and consumer goods demand.

₹00

Latest IPO GMP

Last updated on 22 Dec 2025 19.44

₹98

IPO Offer Price

*cut off price

--

Listing Price

Listing date is Updated soon. So, we will update later..

Expert Opinions

Market sentiment for Phytochem Remedies IPO is neutral to positive, reflecting steady SME interest amid India’s manufacturing growth, though subdued grey market activity signals cautious investor mood. Company strengths include consistent revenue growth from ₹20.83 crore in FY23 to ₹36.81 crore in FY25, PAT surge of 94% to ₹4.48 crore, high ROE of 34.07%, and operations in pharma/FMCG packaging with strong EBITDA margins of 23.78%. Risks encompass elevated leverage (debt-equity 1.42x), modest scale, working capital intensity, client concentration, and execution risks on capex.

Valuation analysis of Phytochem Remedies IPO in 2025 shows a Return on Equity (ROE) of 34.07%, ROCE of 25.29%, and Net Asset Value (NAV) of ₹41.71, with attractive P/E of 17.24x and P/B of 2.35x versus peers. Long-term investment perspective favors growth from packaging demand (11% CAGR), PLI schemes, and capex for machinery (₹13.60 crore) plus debt reduction, positioning for margin expansion.

Investor Considerations

Investors in Phytochem Remedies IPO should examine the company’s improving fundamentals, with revenue growing 12% to ₹36.81 crore and PAT surging 94% to ₹4.48 crore in FY 2025, alongside H1 FY26 revenue of ₹25.01 crore and PAT of ₹3.75 crore. Sector outlook is strong, fueled by global API demand, India’s pharma export growth, and PLI schemes boosting domestic manufacturing.

Valuation analysis of Phytochem Remedies IPO in 2025 shows a Price to Book Value of 2.35, PAT Margin of 12.25%, and Debt/Equity ratio of 1.42, offering attractive pricing with moderate leverage. Growth prospects include capex for machinery (₹13.60 crore), civil construction (₹5.88 crore), and debt repayment (₹9.37 crore), enhancing capacity and export reach. Risk factors encompass raw material volatility, regulatory compliance, and competition in the fragmented API space. Long-term investors gain from pharma tailwinds, while short-term goals face execution and market risks.